Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has reported E.P.S. of $0.36 for its second fiscal quarter (ending June 30) versus $-0.02 for the same period a year ago. Relative to the consensus estimate of $0.39, this was a shortfall of $-0.03. For the latest four quarters through June 30, E.P.S. were $0.10 compared to $0.80 a year ago — a decline of -88%.
Recent Price Action
On 8/6/24, Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock declined slightly by -0.1%, closing at $27.88. NORMAL trading volume accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -8.9% during the last week.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Supernus Pharmaceuticals has a neutral Appreciation Score of 46 and a neutral Power Rating of 58, triggering the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment